Get the Stockscreener App
9.055
4.56%
0.395
Pre-market:
9.25
0.195
+2.15%
Lexeo Therapeutics Inc stock is traded at $9.055, with a volume of 829.83K.
It is up +4.56% in the last 24 hours and up +8.44% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$8.66
Open:
$8.57
24h Volume:
829.83K
Relative Volume:
0.68
Market Cap:
$660.90M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-3.1969
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-5.97%
1M Performance:
+8.44%
6M Performance:
+192.10%
1Y Performance:
+34.15%
1-Day Range:
$8.39
$9.21
1-Week Range:
$8.30
$10.04
52-Week Range:
$1.45
$10.38
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.055 | 632.07M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Lexeo Therapeutics (Nasdaq: LXEO) plans virtual PKP2-ACM event at 22nd CVCT Forum Dec. 9 - Stock Titan
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
How resilient is Lexeo Therapeutics Inc. stock in market downturnsJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Will Lexeo Therapeutics Inc. stock deliver shareholder valueExit Point & Consistent Income Trade Ideas - moha.gov.vn
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Expert Approved Momentum Ideas - BỘ NỘI VỤ
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics CEO Makes Significant Stock Sale! - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock - Investing.com
Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
CEO Townsend Surrenders 1,127 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target - MarketScreener
Equities Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
Real time pattern detection on Lexeo Therapeutics Inc. stockMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Lexeo Therapeutics Inc. price bounce be sustainableGold Moves & Daily Entry Point Alerts - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Officer Tai Files To Sell 386 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Institutional Investors Are Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Biggest Bettors and Were Rewarded After Last Week's US$70m Market Cap Gain - 富途牛牛
Lexeo Therapeutics Insiders Benefitted From Selling Stock At US$7.01 - simplywall.st
Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile - TipRanks
V2Y Corporation Ltd Expands into Renewable Energy and Commodities - The Globe and Mail
Can Lexeo Therapeutics Inc. stock withstand economic slowdownWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Using data filters to optimize entry into Lexeo Therapeutics Inc.Portfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Is Lexeo Therapeutics Inc. meeting your algorithmic filter criteriaTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
Long term hold vs stop loss in Lexeo Therapeutics Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
Should you hold or exit Lexeo Therapeutics Inc. now2025 Fundamental Recap & Precise Trade Entry Recommendations - newser.com
How Lexeo Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Using Python tools to backtest Lexeo Therapeutics Inc. strategiesMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
What to do if you’re stuck in Lexeo Therapeutics Inc.Market Activity Report & Real-Time Stock Price Movement Reports - newser.com
Is Lexeo Therapeutics Inc a good long term investmentStop Loss Placement Tips & Subscribe for Free Weekly Winners - earlytimes.in
Why hedge funds are buying Lexeo Therapeutics Inc. stock2025 Year in Review & Momentum Based Trading Ideas - newser.com
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):